FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Anti-Aging Skin Stack

Anti-Aging & Longevityintermediate

83

상호작용

83
Share
펩타이드

3

일 평균 mcg

5,800

수준

intermediate

추가됨

May 17, 2026

개요

The Anti-Aging Skin Stack combines the three most evidence-backed peptides for skin aging and longevity into a comprehensive protocol that targets collagen synthesis, cellular aging, and GH-driven tissue regeneration simultaneously. GHK-Cu (glycyl-L-histidyl-L-lysine copper) is the anchor of this stack. As a copper-binding tripeptide that naturally declines with age (from ~200ng/mL at age 20 to ~80ng/mL at 60), GHK-Cu activates over 4,000 human genes — more than any other known compound. For skin, it promotes collagen and elastin synthesis, activates fibroblasts, reduces inflammation, and protects against UV damage. Both topical and injectable forms have peer-reviewed human data supporting skin quality improvements. Epithalon works at the cellular aging level. By activating telomerase and regulating the pineal gland''s circadian signaling, it slows two fundamental mechanisms of skin aging: telomere shortening (which drives cellular senescence) and circadian rhythm disruption (which impairs the nighttime skin repair cycle). Epithalon is used in 10-day courses rather than continuously. CJC-1295 provides the GH axis component. GH decline is one of the primary drivers of skin thinning, reduced collagen density, and decreased healing capacity with age. By amplifying nocturnal GH pulses, CJC-1295 increases IGF-1-driven collagen production throughout the body, including skin. The combination of GHK-Cu (direct collagen synthesis) and CJC-1295 (hormonal collagen support) creates a more sustained and comprehensive collagen protection effect.

용량 프로토콜

GHK-Cu

Every day· subcutaneous or topical

GHK-Cu에 대한 자세한 내용 →

500 mcg

1회 용량당

Epithalon

daily (10-day course)· subcutaneous

Epithalon에 대한 자세한 내용 →

5,000 mcg

1회 용량당

CJC-1295

daily (before bed)· subcutaneous

CJC-1295에 대한 자세한 내용 →

300 mcg

1회 용량당

목표 및 증거

Skin anti-agingCollagen productionReduced wrinklesSkin elasticityCellular longevity
증거 등급:인체 데이터

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.